PUBLICATIONS & ABSTRACTS: CLINICAL EVIDENCE
100s of extensive peer reviewed publications and studies utilizing MammaPrint + BluePrint have observed benefits from treatment in the following areas of clinical utility:
Scientific evidence for clinical utility.
By continually expanding and strengthening our database of proven research including 20+ years of clinical validation and 200+ research collaborations, we have gained widespread trust in the precision, accuracy and quality of our MammaPrint® and BluePrint® test suite.
Evidence
The EORTC 10041/BIG 03-04 MINDACT Trial is Feasible: Results of the Pilot Phase
PUBLICATION: European Journal of Cancer, December 2011, Volume 47, Issue 18, Pages 2742–2749. AUTHORS: Emiel Rutgers, Martine J. Piccart-Gebhart, Jan Bogaerts, Suzette Delaloge, Laura Van ‘t Veer, Isabel Teresa Rubio, Giuseppe Viale, Alastair M. Thompson, Rodolfo Passalacqua, Ulrike Nitz, Anita Vindevoghel, Jean-Yves Pierga, Peter M. Ravdin, Gustavo Werutsky, Fatima Cardoso Read More
Use of a Genomic Test (MammaPrint™) in Daily Clinical Practice to Assist in Risk Stratification of Young Breast Cancer Patients
PUBLICATION: Arch Gynecol Obstet (2011) 283: 597. https://doi.org/10.1007/s00404-010-1454-9. AUTHORS: Kunz, G. SUMMARY: 44 patients had MammaPrint results and were eligible for the analysis. The results revealed a low risk result in 29 patients and a high risk result in 15 patients. Read more: Kunz_2011_Arch Gynecol Obstet._Use of a Genomic Test Read More
Gene Expression Profiles from Formalin Fixed Paraffin Embedded Breast Cancer Tissue are Largely Comparable to Fresh Frozen Matched Tissue
PUBLICATION: PLoS One. 2011 Feb 11;6(2):e17163. doi: 10.1371/journal.pone.0017163. AUTHORS: Mittempergher L., de Ronde J.J., Nieuwland M., Kerkhoven R.M., Simon I., Rutgers E.J., Wessels L.F., Van't Veer L.J. SUMMARY: We demonstrate that data generated from FFPE material with the DASL assay, if properly processed, are comparable to data extracted from the Read More
Cost-effectiveness of 70-gene MammaPrint Signature in Node-Negative Breast Cancer
PUBLICATION: Am J Manag Care. 2010 Dec 1;16(12):e333-42. AUTHORS: Chen E., Tong K.B., Malin J.L. SUMMARY: 70-gene signature reclassified 29% of patients and spared 10% of patients from chemotherapy. Results of this modeling analysis suggest that treatment guided by 70-gene signature may be associated with a decrease in chemotherapy use Read More
Identification of a Low-Risk Subgroup of HER-2-Positive Breast Cancer by the 70-gene Prognosis Signature
PUBLICATION: Br J Cancer. 2010 Dec 7; 103(12): 1788–1793. Published online 2010 Nov 16. doi: 10.1038/sj.bjc.6605916. AUTHORS: M. Knauer, F. Cardoso, J. Wesseling, P.L. Bedard, S.C. Linn, E.J.T. Rutgers, and L.J. van't Veer Background: Overexpression of HER-2 is observed in 15–25% of breast cancers, and is associated with increased risk Read More
Comparison of MammaPrint and TargetPrint Results with Clinical Parameters in German Patients with Early Stage Breast Cancer
PUBLICATION: Int J Mol Med. 2010 Dec;26(6):837-43. AUTHORS: Gevensleben H., Göhring U.J., Büttner R., Heukamp L.C., Kunz G., Dimpfl T., Jackisch C., Ortmann O., Albert U.S., Bender R., De Snoo F., Krijgsman O., Glas A.M., Ergönenc Y.H., Vogel C., Dykgers A., Langwieder C., Rees M., Anzeneder T. SUMMARY: Thirty-two percent Read More
Biological Functions of the Genes in the MammaPrint® Breast Cancer Profile Reflect the Hallmarks of Cancer
PUBLICATION: Biomarker Insights. 2010 Nov 28;5:129-38. doi: 10.4137/BMI.S6184. AUTHORS: Tian S., Roepman P., Van't Veer L.J., Bernards R., de Snoo F., Glas A.M. SUMMARY: The study included 3090 clinical low-risk patients with unifocal and 238 patients with multifoGenes in the MammaPrint gene signature comprehensively measure the six hallmarks of cancer-related Read More
